BackClarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Other Current Liabilities

Clarus Therapeutics Holdings's other current liabilities is $9.8M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$9.83M
↓ 10.62% YoYΔ $-1.17M vs prior year quarter

Peer average

Loading

Clarus Therapeutics Holdings Other Current Liabilities History

Loading

Clarus Therapeutics Holdings vs. peers: Other Current Liabilities Comparison

Loading

Clarus Therapeutics Holdings Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Clarus Therapeutics Holdings (CRXT) FAQ

As of the most recent data (June 2022), CRXT shows a other current liabilities of $9.8M. That compares with $11M in the prior-year period — down 10.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRXT's other current liabilities is now $9.8M (was $11M) — a 10.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Clarus Therapeutics Holdings is outperforming or lagging.

Tracking CRXT's other current liabilities over time shows whether Clarus Therapeutics Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $9.8M That compares with $11M in the prior-year period — down 10.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Clarus Therapeutics Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $9.8M) with ownership activity and broader fundamentals.